

## Echo Therapeutics, Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis

URL:	<a href="https://marketpublishers.com/r/ECBACD09FC2BEN.html">https://marketpublishers.com/r/ECBACD09FC2BEN.html</a>
Date:	October 15, 2018
Pages:	50
Price:	US\$ 499.00
ID:	ECBACD09FC2BEN

Echo Therapeutics, Inc. Due Diligence Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Echo Therapeutics, Inc. and its competitors. This provides our Clients with a clear understanding of Echo Therapeutics, Inc. position in the **Pharmaceuticals and Biotechnology Industry**.

- The report contains detailed information about Echo Therapeutics, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Echo Therapeutics, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.
- The Echo Therapeutics, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.
- In the part that describes Echo Therapeutics, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Echo Therapeutics, Inc. business.

### About Echo Therapeutics, Inc.

Echo Therapeutics, Inc. operates as a medical device and specialty pharmaceutical company. The company is developing a wireless, transdermal continuous glucose monitoring (tCGM) system for use in clinical settings and for people with diabetes together with a range of transdermal reformulations of specialty pharmaceutical products.

### Medical Devices

The company is developing its Prelude SkinPrep System (Prelude) as a platform technology to allow painless skin permeation that would enable two applications: analyte extraction, with the Symphony tCGM System (Symphony) for needle-free, continuous glucose monitoring in hospital patients as the first application; and needle-free drug delivery, with the delivery of lidocaine as the first application. Symphony includes the Prelude SkinPrep System for needle-free skin permeation and its patented continuous transdermal glucose biosensor.

#### Prelude SkinPrep System

The company is developing Prelude as a transdermal skin permeation device for its Symphony tCGM System to improve the flow of interstitial fluids and molecules across the protective membrane of the stratum corneum, the outmost protective layer of the skin. Prelude incorporates its patented skin permeation control technology into a hand-held device used to prepare a small area of the skin for the non-invasive sensor components of Symphony.

**Symphony tCGM System:** The company's primary medical device program in analyte extraction is its Symphony tCGM System, a needle-free, wireless, transdermal continuous glucose monitoring system designed to provide real-time blood glucose data. Symphony incorporates Prelude (its proprietary skin permeation device), a transdermal sensor, and wireless transmission, and data display technologies.

**Symphony Wireless Transmitter:** The Symphony transmitter assembly consists of coupling hydrogel/chemistry, sensor electrodes, and integrated electronics. To preserve data integrity and save power, the assembly digitizes, stores and transmits discrete, coded signals via a wireless link to the Symphony receiving monitor.

**Symphony Monitor:** The company's Symphony monitor receives digitally coded data from the transmitter assembly and then decodes the data once every minute. Once a reference blood glucose value is entered manually (a calibration) after a one hour warm-up period, the decoded data are converted to blood glucose reading by a built-in data algorithm. The Symphony monitor displays the date, time of day, sensor current, blood glucose reading, and rate of increase or decrease, amount of time the transmitter has been switched on, battery status, and any alarm or error modes.

#### Specialty Pharmaceuticals

The company's specialty pharmaceuticals pipeline is based on its proprietary AzoneTS transdermal drug reformulation technology. AzoneTS is a nontoxic, nonirritating skin penetration enhancer. AzoneTS improves lipid membrane fluidity in the stratum corneum layer of the skin, thereby decreasing the diffusion resistance to topically applied therapeutics. AzoneTS is a chemical combination of pyrrolidone and decylmethyl sulfoxide. The company's proprietary synergistic chemical combination enables AzoneTS to be a skin penetration enhancer at low concentration levels.

**Durhalieve:** The company's primary drug candidate is Durhalieve, an AzoneTS formulation of triamcinolone acetonide, a medium potency corticosteroid approved for treatment of corticosteroid-responsive dermatoses. In addition to Durhalieve for the treatment of corticosteroid-responsive dermatoses, it develops Durhalieve as a treatment for keloid scarring.

#### Partnerships

In 2009, the company has entered into a licensing agreement with Ferndale Pharma Group, Inc. (Ferndale), which offers skincare and topical therapeutic products. Under the terms of the agreement, the company granted Ferndale the right to develop, market, sell and distribute Prelude for skin preparation prior to the application of topical 4% lidocaine cream prior to a range of needle-based medical procedures in North America and the United Kingdom.

In 2009, the company has also entered into a license agreement with Handok Pharmaceuticals Co., Ltd. (Handok), the diabetes care-focused pharmaceutical company in South Korea. The company granted Handok the right to develop, market, sell, and distribute Symphony to medical facilities and diabetics in South Korea.

## History

Echo Therapeutics, Inc. was founded in 1989.

The above Company Fundamental Report is a half-ready report and contents are subject to change. It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

## Table of Content

### RESEARCH METHODOLOGY

### DISCLAIMER

## 1. ECHO THERAPEUTICS, INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

## 2. ECHO THERAPEUTICS, INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

## 3. ECHO THERAPEUTICS, INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

## 4. ECHO THERAPEUTICS, INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
  - 4.1.1. Income Statement
  - 4.1.2. Balance Sheet
  - 4.1.3. Cash Flow
- 4.2. Financial Ratios
  - 4.2.1. Profitability
  - 4.2.2. Margin Analysis
  - 4.2.3. Asset Turnover

- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

## **5. ECHO THERAPEUTICS, INC. COMPETITORS AND INDUSTRY ANALYSIS**

- 5.1. Echo Therapeutics, Inc. Direct Competitors
- 5.2. Comparison of Echo Therapeutics, Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of Echo Therapeutics, Inc. and Direct Competitors Stock Charts
- 5.4. Echo Therapeutics, Inc. Industry Analysis
  - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  - 5.4.2. Echo Therapeutics, Inc. Industry Position Analysis

## **6. ECHO THERAPEUTICS, INC. NEWS & EVENTS**

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

## **7. ECHO THERAPEUTICS, INC. EXPERTS REVIEW<sup>1</sup>**

- 7.1. Experts Opinion
- 7.2. Experts Estimates

## **8. ECHO THERAPEUTICS, INC. ENHANCED SWOT ANALYSIS<sup>2</sup>**

## **9. UNITED STATES PESTEL ANALYSIS<sup>2</sup>**

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

## **10. ECHO THERAPEUTICS, INC. IFE, EFE, IE MATRICES<sup>2</sup>**

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

## **11. ECHO THERAPEUTICS, INC. PORTER FIVE FORCES ANALYSIS<sup>2</sup>**

## **12. ECHO THERAPEUTICS, INC. VRIO ANALYSIS<sup>2</sup>**

## **APPENDIX: RATIO DEFINITIONS**

### **LIST OF TABLES**

Echo Therapeutics, Inc. Key Facts  
Profitability  
Management Effectiveness

Income Statement Key Figures  
Balance Sheet Key Figures  
Cash Flow Statement Key Figures  
Financial Performance Abbreviation Guide  
Echo Therapeutics, Inc. Key Executives  
Key Executives Biographies<sup>1</sup>  
Key Executives Compensations<sup>1</sup>  
Echo Therapeutics, Inc. Major Shareholders  
Echo Therapeutics, Inc. History  
Echo Therapeutics, Inc. Products  
Revenues by Segment  
Revenues by Region  
Echo Therapeutics, Inc. Offices and Representations  
Echo Therapeutics, Inc. SWOT Analysis  
Yearly Income Statement Including Trends  
Income Statement Latest 4 Quarters Including Trends  
Yearly Balance Sheet Including Trends  
Balance Sheet Latest 4 Quarters Including Trends  
Yearly Cash Flow Including Trends  
Cash Flow Latest 4 Quarters Including Trends  
Echo Therapeutics, Inc. Profitability Ratios  
Margin Analysis Ratios  
Asset Turnover Ratios  
Credit Ratios  
Long-Term Solvency Ratios  
Financial Ratios Growth Over Prior Year  
Echo Therapeutics, Inc. Capital Market Snapshot  
Echo Therapeutics, Inc. Direct Competitors Key Facts  
Direct Competitors Profitability Ratios  
Direct Competitors Margin Analysis Ratios  
Direct Competitors Asset Turnover Ratios  
Direct Competitors Credit Ratios  
Direct Competitors Long-Term Solvency Ratios  
Pharmaceuticals and Biotechnology Industry Statistics  
Echo Therapeutics, Inc. Industry Position  
Company vs. Industry Income Statement Analysis  
Company vs. Industry Balance Sheet Analysis  
Company vs. Industry Cash Flow Analysis  
Company vs. Industry Ratios Comparison  
Echo Therapeutics, Inc. Consensus Recommendations<sup>1</sup>  
Analyst Recommendation Summary<sup>1</sup>  
Price Target Summary<sup>1</sup>  
Experts Recommendation Trends<sup>1</sup>  
Revenue Estimates Analysis<sup>1</sup>  
Earnings Estimates Analysis<sup>1</sup>  
Historical Surprises<sup>1</sup>  
Revenue Estimates Trend<sup>1</sup>  
Earnings Estimates Trend<sup>1</sup>  
Revenue Revisions<sup>1</sup>

## LIST OF FIGURES

Echo Therapeutics, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit Profit Margin Chart

Operating Margin Chart  
Return on Equity (ROE) Chart  
Return on Assets (ROA) Chart  
Debt to Equity Chart  
Current Ratio Chart  
Echo Therapeutics, Inc. 1-year Stock Charts  
Echo Therapeutics, Inc. 5-year Stock Charts  
Echo Therapeutics, Inc. vs. Main Indexes 1-year Stock Chart  
Echo Therapeutics, Inc. vs. Direct Competitors 1-year Stock Charts  
Echo Therapeutics, Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.

The complete financial data is available for publicly traded companies.

### I would like to order:

**Product name:** Echo Therapeutics, Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis  
**Product link:** <https://marketpublishers.com/r/ECBACD09FC2BEN.html>  
**Product ID:** ECBACD09FC2BEN  
**Price:** US\$ 499.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/ECBACD09FC2BEN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**